IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0390460
(2010-08-16)
|
등록번호 |
US-8507195
(2013-08-13)
|
국제출원번호 |
PCT/US2010/045574
(2010-08-16)
|
§371/§102 date |
20120430
(20120430)
|
국제공개번호 |
WO2011/022316
(2011-02-24)
|
발명자
/ 주소 |
- Richer, Jennifer
- Cochrane, Dawn
- Anderson, Steven M.
|
출원인 / 주소 |
- The Regents of the University of Colorado
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
1 인용 특허 :
0 |
초록
▼
The invention provides methods of diagnosing and treating cancer in a subject. The inventors have identified a series of dysregulated miRNAs that are indicative of triple-negative breast cancer. In some embodiments, the invention further provides for the administration of a cancer therapy to the sub
The invention provides methods of diagnosing and treating cancer in a subject. The inventors have identified a series of dysregulated miRNAs that are indicative of triple-negative breast cancer. In some embodiments, the invention further provides for the administration of a cancer therapy to the subject.
대표청구항
▼
1. A method of identifying “triple-negative” breast cancer in a subject comprising: (a) obtaining a breast cancer tissue sample from said subject; and(b) assessing said sample for one or more miRNAs selected from the group consisting of miR-193b, miR-34a, miR-301a, miR-148a and/or miR-15b;wherein de
1. A method of identifying “triple-negative” breast cancer in a subject comprising: (a) obtaining a breast cancer tissue sample from said subject; and(b) assessing said sample for one or more miRNAs selected from the group consisting of miR-193b, miR-34a, miR-301a, miR-148a and/or miR-15b;wherein decreased levels of one or more of miR-193b, miR-34a, miR-301a, miR-148a and/or miR-15b in said sample, as compared to a luminal breast cancer, indicates that said subject has a “triple-negative” breast cancer. 2. The method of claim 1, wherein said sample is a biopsy or resected tumor tissue. 3. The method of claim 1, wherein one, two, three or four of said miRNAs are assessed. 4. The method of claim 1, wherein each of miR-193b, miR-34a, miR-301a, miR-148a and miR-15b are assessed. 5. The method of claim 1, wherein one, two, three or four of said miRNAs are decreased. 6. The method of claim 1, wherein each of miR-193b, miR-34a, miR-301a, miR-148a and miR-15b are decreased. 7. The method of claim 1, wherein said subject is determined not to have “triple-negative” breast cancer, and further comprising administering to said subject a treatment for ER-positive breast cancer. 8. The method of claim 1, wherein said subject is determined to have “triple-negative” breast cancer, and further comprising administering to said subject a treatment for “triple-negative” breast cancer. 9. The method of claim 8, wherein if said subject exhibits reduced miR-193b, said subject is treated with a fatty acid synthase inhibitor. 10. The method of claim 9, wherein said inhibitor is miR-193b, c75 or Orlistat®. 11. The method of claim 8, wherein if said subject exhibits reduced miR-34a, said subject is treated with miR-34a. 12. The method of claim 8, wherein if said subject exhibits reduced miR-301a, said subject is treated with miR-301a. 13. The method of claim 8, wherein if said subject exhibits reduced miR-148a, said subject is treated with miR-148a. 14. The method of claim 8, wherein if said subject exhibits reduced miR-15b, said subject is treated with miR-15b.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.